ACLARIS THERAPEUTICS INC.
1,985.46
USD
(+1.04%)
03/22/2025 - 06:34
Open 15 min delayed data - NASDAQ Stocks
| Open: | 1,965.09 |
| Change: | +20.33 |
| Volume: | 16,948 |
| Low: | 1,964.03 |
| High: | 1,992.12 |
| High / Low range: | 28.09 |
| Type: | Stocks |
| Ticker: | ACRS |
| ISIN: |
ACLARIS THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
ACLARIS THERAPEUTICS INC. - More news...
ACLARIS THERAPEUTICS INC. - More news...
- 11/18/2024 - 13:50 Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
- 01/22/2024 - 14:31 Thinking about buying stock in KE Holdings, Ford Motor, Vertiv Holdings, Cadrenal Therapeutics, or Aclaris Therapeutics?
-
01/19/2021 - 22:39
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 01-19-2021
-
07/20/2020 - 21:33
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 07-20-2020
-
06/17/2020 - 20:16
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 06-17-2020
-
01/10/2020 - 20:57
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 01-10-2020
-
10/29/2019 - 20:42
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 10-29-2019
-
10/22/2019 - 20:16
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 10-22-2019
-
10/07/2019 - 21:13
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 10-07-2019
- 09/28/2019 - 14:00 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NYSE: ACRS) and Encourages Aclaris Investors to Contact the Firm
- 09/26/2019 - 20:45 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS
- 09/26/2019 - 00:48 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm
- 09/24/2019 - 17:05 LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm
- 09/12/2019 - 22:20 GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action – ACRS
- 09/09/2019 - 16:55 Shareholder Alert: Robbins Arroyo LLP Reminds Shareholders That Aclaris Therapeutics, Inc. (ACRS) Sued for Misleading Shareholders
- 08/24/2019 - 14:10 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS
-
08/13/2019 - 22:08
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 08-13-2019
- 08/02/2019 - 22:30 ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ACRS
- 07/31/2019 - 22:54 IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- 07/31/2019 - 21:47 LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm
-
07/01/2019 - 21:37
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 07-01-2019
- 04/18/2018 - 11:35 Investor Expectations to Drive Momentum within Casella Waste, Prologis, Flushing Financial, AMERISAFE, Aclaris Therapeutics, and NanoString Technologies — Discovering Underlying Factors of Influence
- 03/29/2018 - 12:10 Analysis: Positioning to Benefit within TopBuild, MarketAxess, Provident Financial Services, SailPoint Technologies, Aclaris Therapeutics, and VOXX International — Research Highlights Growth, Revenue, and Consolidated Results
- 08/08/2017 - 05:50 Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call
- 05/09/2017 - 13:15 Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call
- 01/26/2017 - 13:00 Aclaris Therapeutics Announces Appointment of Andrew Powell to Board of Directors
- 01/03/2017 - 13:00 Aclaris to Present at 35th Annual J.P. Morgan Healthcare Conference
- 12/07/2016 - 13:00 Aclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001, an Investigational JAK Inhibitor, for the Treatment of Alopecia Totalis and Alopecia Universalis
- 11/22/2016 - 13:00 Aclaris Therapeutics to Attend Upcoming Investor Conferences
- 11/18/2016 - 00:03 Aclaris Announces Pricing of Public Offering of Common Stock
